{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AS%2B&page=49",
    "query": {
      "intervention": "AS+",
      "page": 49
    },
    "page_size": 10
  },
  "pagination": {
    "page": 49,
    "page_size": 10,
    "total_count": 48465,
    "total_pages": 4847,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AS%2B&page=50&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AS%2B&page=48&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T22:55:18.666Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07058012",
      "title": "A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colo-rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "cemiplimab plus fianlimab",
          "type": "DRUG"
        },
        {
          "name": "cemiplimab + REGN7075",
          "type": "DRUG"
        },
        {
          "name": "ctDNA testing",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NSABP Foundation Inc",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2026-04-17",
      "completion_date": "2029-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-11-03T22:55:18.666Z",
      "location_count": 13,
      "location_summary": "Gainesville, Florida • Iowa City, Iowa • Kansas City, Kansas + 9 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07058012"
    },
    {
      "nct_id": "NCT07282119",
      "title": "Can EmeraldLED Reshape Your Body With Continued Use?",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Body Composition"
      ],
      "interventions": [
        {
          "name": "EmeraldLED",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Efforia, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-08-29",
      "completion_date": "2026-08-29",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-11-03T22:55:18.666Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07282119"
    },
    {
      "nct_id": "NCT00571519",
      "title": "Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "rivoglitazone HCl",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "pioglitazone HCl",
          "type": "DRUG"
        },
        {
          "name": "pioglitazone HCl 45 mg",
          "type": "DRUG"
        },
        {
          "name": "metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2007-11-14",
      "completion_date": "2008-05-23",
      "has_results": true,
      "last_update_posted_date": "2021-05-26",
      "last_synced_at": "2026-11-03T22:55:18.666Z",
      "location_count": 18,
      "location_summary": "Huntsville, Alabama • San Diego, California • San Francisco, California + 14 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Ridgefield",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00571519"
    },
    {
      "nct_id": "NCT00472719",
      "title": "Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VRC-HIVADV027-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRC-HIVADV038-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRC-HIVDNA044-00-VP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 17,
      "start_date": "2007-08",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-11-03T22:55:18.666Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • San Francisco, California • New York, New York + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00472719"
    },
    {
      "nct_id": "NCT07166419",
      "title": "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive",
        "Recurrent Acute Lymphoblastic Leukemia",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive",
        "Recurrent Indolent Non-Hodgkin Lymphoma",
        "Recurrent Lymphoblastic Lymphoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Transformed Chronic Lymphocytic Leukemia",
        "Refractory Acute Lymphoblastic Leukemia",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive",
        "Refractory Indolent Non-Hodgkin Lymphoma",
        "Refractory Lymphoblastic Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Transformed Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Autologous Anti-CD19/CD20/CD22 CAR T-cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Pheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2026-01-14",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-11-03T22:55:18.666Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07166419"
    },
    {
      "nct_id": "NCT01601665",
      "title": "Post Approval Study of the AcrySof® IQ Toric Intraocular Lens (IOL) Models SN6AT6-SN6AT9",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cataracts",
        "Astigmatism"
      ],
      "interventions": [
        {
          "name": "SN6AT6 Intraocular Lens",
          "type": "DEVICE"
        },
        {
          "name": "SN6AT7 Intraocular Lens",
          "type": "DEVICE"
        },
        {
          "name": "SN6AT8 Intraocular Lens",
          "type": "DEVICE"
        },
        {
          "name": "SN6AT9 Intraocular Lens",
          "type": "DEVICE"
        },
        {
          "name": "SN60WF Intraocular Lens",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 477,
      "start_date": "2012-02",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-08-04",
      "last_synced_at": "2026-11-03T22:55:18.666Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01601665"
    },
    {
      "nct_id": "NCT04489628",
      "title": "Tele-health Enabled Clinical Trial for COVID-19",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV Infection"
      ],
      "interventions": [
        {
          "name": "Vitamin D3 or Placebo",
          "type": "DRUG"
        },
        {
          "name": "Doctella telehealth monitoring",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-08-01",
      "completion_date": "2021-06-01",
      "has_results": false,
      "last_update_posted_date": "2022-02-07",
      "last_synced_at": "2026-11-03T22:55:18.666Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04489628"
    },
    {
      "nct_id": "NCT03900728",
      "title": "Auriculotherapy During Medication Abortion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Abortion Early"
      ],
      "interventions": [
        {
          "name": "Auriculotherapy with needles",
          "type": "DEVICE"
        },
        {
          "name": "Auriculotherapy with beads",
          "type": "DEVICE"
        },
        {
          "name": "Placebo Adhesive disks",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 138,
      "start_date": "2019-04-01",
      "completion_date": "2020-03-30",
      "has_results": true,
      "last_update_posted_date": "2021-07-06",
      "last_synced_at": "2026-11-03T22:55:18.666Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03900728"
    },
    {
      "nct_id": "NCT05577728",
      "title": "Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "New use of semaglutide injection",
          "type": "DRUG"
        },
        {
          "name": "New initiation of \"standard of care\" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2316,
      "start_date": "2021-07-01",
      "completion_date": "2022-10-31",
      "has_results": false,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-11-03T22:55:18.666Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05577728"
    },
    {
      "nct_id": "NCT02240407",
      "title": "Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pompe Disease"
      ],
      "interventions": [
        {
          "name": "Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase",
          "type": "GENETIC"
        },
        {
          "name": "Rapamycin",
          "type": "DRUG"
        },
        {
          "name": "saline",
          "type": "OTHER"
        },
        {
          "name": "Rituxan",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Lidocaine",
          "type": "DRUG"
        },
        {
          "name": "LMX 4 Topical Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 2,
      "start_date": "2017-10-17",
      "completion_date": "2021-08-26",
      "has_results": false,
      "last_update_posted_date": "2022-04-05",
      "last_synced_at": "2026-11-03T22:55:18.666Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02240407"
    }
  ]
}